Jarislowsky Fraser Ltd decreased its stake in Sanofi (NYSE:SNY) by 8.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 176,169 shares of the company’s stock after selling 15,475 shares during the period. Jarislowsky Fraser Ltd’s holdings in Sanofi were worth $8,440,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the stock. Harbour Capital Advisors LLC acquired a new stake in shares of Sanofi during the first quarter valued at approximately $113,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Sanofi by 95.8% in the first quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock valued at $210,000 after buying an additional 2,087 shares during the last quarter. Huntington National Bank boosted its stake in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock valued at $202,000 after buying an additional 147 shares during the last quarter. Finally, BLB&B Advisors LLC acquired a new stake in shares of Sanofi during the first quarter valued at approximately $202,000. Institutional investors and hedge funds own 9.96% of the company’s stock.
Shares of Sanofi (NYSE SNY) traded up 0.30% during mid-day trading on Friday, reaching $47.55. 717,957 shares of the company traded hands. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The firm’s 50 day moving average price is $47.99 and its 200-day moving average price is $46.11. The company has a market capitalization of $119.42 billion, a P/E ratio of 11.23 and a beta of 0.88.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities analysts predict that Sanofi will post $3.26 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was reported by BNB Daily and is the property of of BNB Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/13/jarislowsky-fraser-ltd-sells-15475-shares-of-sanofi-sny-updated-updated-updated.html.
Several equities analysts recently issued reports on SNY shares. Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. BidaskClub raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, April 20th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 target price (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, Berenberg Bank lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.